Multi‐proteomic analyses of 5xFAD mice reveal new molecular signatures of early‐stage Alzheimer's disease
Authors:
Open Access
- 4 March 2024
- journal article
- research article
- Published by Wiley in Aging Cell
- Vol. 23 (6) , e14137
Abstract
An early diagnosis of Alzheimer's disease is crucial as treatment efficacy is limited to the early stages. However, the current diagnostic methods are limited to mid or later stages of disease development owing to the limitations of clinical examinations and amyloid plaque imaging. Therefore, this study aimed to identify molecular signatures including blood plasma extracellular vesicle biomarker proteins associated with Alzheimer's disease to aid early‐stage diagnosis. The hippocampus, cortex, and blood plasma extracellular vesicles of 3‐ and 6‐month‐old 5xFAD mice were analyzed using quantitative proteomics. Subsequent bioinformatics and biochemical analyses were performed to compare the molecular signatures between wild type and 5xFAD mice across different brain regions and age groups to elucidate disease pathology. There was a unique signature of significantly altered proteins in the hippocampal and cortical proteomes of 3‐ and 6‐month‐old mice. The plasma extracellular vesicle proteomes exhibited distinct informatic features compared with the other proteomes. Furthermore, the regulation of several canonical pathways (including phosphatidylinositol 3‐kinase/protein kinase B signaling) differed between the hippocampus and cortex. Twelve potential biomarkers for the detection of early‐stage Alzheimer's disease were identified and validated using plasma extracellular vesicles from stage‐divided patients. Finally, integrin α‐IIb, creatine kinase M‐type, filamin C, glutamine γ‐glutamyltransferase 2, and lysosomal α‐mannosidase were selected as distinguishing biomarkers for healthy individuals and early‐stage Alzheimer's disease patients using machine learning modeling with approximately 79% accuracy. Our study identified novel early‐stage molecular signatures associated with the progression of Alzheimer's disease, thereby providing novel insights into its pathogenesis.Keywords
All Related Versions
Funding Information
- Ministry of Science and ICT, South Korea (23‐BR‐02‐03, 23‐BR‐04‐02, 23‐BR‐02‐13, 23‐BR‐05‐01, 22‐CoE‐BT‐02, A0801043001)
This publication has 68 references indexed in Scilit:
- The 5XFAD mouse model of Alzheimer’s disease displays age-dependent deficits in habituation to a novel environmentAging Brain, 2023
- Alzheimer's disease drug development pipeline: 2022Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022
- Artificial intelligence for proteomics and biomarker discoveryCell Systems, 2021
- Transglutaminase Type 2 Regulates ER-Mitochondria Contact Sites by Interacting with GRP75Cell Reports, 2018
- Extracellular vesicles in neurodegenerative diseasesMolecular Aspects of Medicine, 2018
- Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinicAlzheimer's & Dementia, 2016
- Introduction to special issue on Advances in blood‐based biomarkers of Alzheimer's diseaseAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2016
- Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profileAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2016
- Linking proteome responses with physiological and biochemical effects in herbicide-exposed Chlamydomonas reinhardtiiJournal of Proteomics, 2012
- Comparative analysis of the secretory proteome of human adipose stromal vascular fraction cells during adipogenesisProteomics, 2010